The U.S. Food and Drug Administration (FDA) has granted approval for the first drug capable of alleviating all manifestations of narcolepsy type 1. This was announced in an official press release from the pharmaceutical company Takeda.
This drug is named ovexorexone (Orzeyful). It possesses the properties of a highly selective orexin OX2 receptor agonist and is intended for oral administration because it can cross the blood-brain barrier.
Since the cause of narcolepsy type 1 is a deficiency of orexin, this drug is classified as pathogenetic therapy. It is approved for use in the adult patient population.
